The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: A systematic review

Journal of Oral and Facial Pain and Headache

Volumn 29, Issue 1, 2015, Pages 7-14

  Boychuk, Darrell G ^a   Goddard, Greg ^b   Mauro, Giovanni ^c   Orellana, Maria F ^b  

^a Clinician TMD Clinic Health Partners   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Cannabinoids; Chronic nonmalignant pain; Management; Neuropathic pain; Systematic review

Indexed keywords

ANALGESIC AGENT; CANNABINOID;

CHRONIC PAIN; DATA BASE; HUMAN; NEURALGIA; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS;

ANALGESICS; BIAS (EPIDEMIOLOGY); CANNABINOIDS; CHRONIC PAIN; DATABASES AS TOPIC; HUMANS; NEURALGIA; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84925284794     PISSN: 23330384     EISSN: 23330376     Source Type: Journal    
DOI: 10.11607/ofph.1274     Document Type: Article

References (41)

1. Guy GW, Whittle BA, Robson P. The Medicinal Uses of Cannabis and Cannabinoids. Chicago: Pharmaceutical Press, 2004.
2. Kalant H. Medicinal use of cannabis: History and current status. Pain Res Manag 2001;6:80-91.
3. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ 2001;323:16-21.
4. Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett 2004;25:14-23.
5. Pollack A. The search for the killer painkiller. The New York Times, February 15, 2005;Sect F:1.
6. Ware MA, Gamsa A, Persson J, Fitzcharles MA. Cannabis for chronic pain: Case series and implications for clinicians. Pain Res Manag 2002;7:95-99.
7. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:13-16.
8. Harstall C. Use of Cannabis or Cannabinoids for Nonmalignant Chronic Pain. Edmonton, Alberta: Alberta Heritage Foundation for Medical Research, Health Technology Assessment. TechNote 42, February 2004.
9. Bagshaw SM, Hagen NA. Medical efficacy of cannabinoids and marijuana: A comprehensive review of the literature. J Palliat Care 2002;18:111-122.
10. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Metaanalysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007;23:17-24.
11. Solaro C, Messmer Uccelli M. Pharmacological management of pain in patients with multiple sclerosis. Drugs 2010;70: 1245-1254.
12. Martin Fontelles MI, Goicoechea Garcia C. Role of cannabinoids in the management of neuropathic pain. CNS Drugs 2008;22:645-653.
13. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics 2009;6:713-737.
14. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009;10:1353-1368.
15. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: A systematic review of randomized trials. Br J Clin Pharmacol 2011;72:735-744.
16. Frank B, Serpell MG, Hughes J, Matthews JNS, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Randomised, crossover, double blind study. BMJ 2008;336: 199-201.
17. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21-29.
18. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-441.
19. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 2013;14:136-148.
20. Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 2012;153:2073-2082.
21. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013;260:984-997.
22. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
23. Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52:483-486.
24. Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 1990;240:1-4.
25. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies. Anaesthesia 2004;59:440-452.
26. Clermont-Gnamien S, Atlani S, Attal N, Le Mercier F, Guirimand F, Brasseur L. The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain. Presse Med 2002; 31:1840-1845.
27. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004;8:173-177.
28. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76: 1664-1669.
29. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-1526.
30. Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. J Neurol 2006;253:1337-1341.
31. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis or chronic neuropathic pain: A randomized controlled trial. CMAJ 2010;182;E694-E701.
32. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9:506-521.
33. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: Depression is a major confounding factor. Diabetes Care 2010;33:128-130.
34. Ellis RJ, ToperoffW, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology 2008;34:672-680.
35. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIVassociated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007;68:515-521.
36. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133:210-220.
37. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-819.
38. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253-257.
39. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. JAMA 2003; 290:1757-1762.
40. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain 2004;112:299-306.
41. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94: 149-158.